The Irish government's decision to provide new drugs for more than 900 patients with cystic fibrosis is likely to cost more than 650 million euros over the next ten years, reported The Irish Times.
According to the news source, the price agreed by the government includes 400 million euros on the drug Orkambi.
The balance is accounted for by the provision of Kalydeco, as well as access to other, as yet undeveloped drugs from its manufacturer, Vertex Pharmaceuticals.
The HSE reached a broad agreement with Vertex on the deal earlier this month, but it was only approved at last week's cabinet meeting.
The cost of the deal has not been officially disclosed, the news source said.
To read more NewsPoints articles, click here.